Together with Erasmus University, we provide unique executive programs and counseling for Health-Tech and Med-Tech start-ups.

We are a science- and quality-focused company with the goal of providing innovative Point of Care and In Vitro Diagnostics technology to medical and health care professionals.

The POC testing market is set to reach $49 billion by 2020 and is growing in all major segments: hospitals, ambulatory care settings, physician offices and home care.
Our Clinical study division is a platform for various (university) clinical chemistry laboratories in the Netherlands, Germany and Belgium.
Together with Erasmus University, we provide unique executive programs and counseling for Health-Tech and Med-Tech start-ups.
We are a science- and quality-focused company with the goal of providing innovative Point of Care and In Vitro Diagnostics technology to medical and health care professionals.
The POC testing market is set to reach $49 billion by 2020 and is growing in all major segments: hospitals, ambulatory care settings, physician offices and home care.
Our Clinical study division is a platform for various (university) clinical chemistry laboratories in the Netherlands, Germany and Belgium.

Our partner in China,

Aeonmed has three R&D centers in Beijing, Shanghai as well as in Pennsylvania, USA. It also has branch companies in Germany and Indonesia. Innovation is always the corporate core competence of the company. By the end of 2016, Aeonmed had totally applied 1158 patents, among which are 747 invention patents. More than 30% of company employees are in R&D department. More than 10% of total sales income is invested into R&D every year.

Monitoring of the vascular stiffness with our Vascular check 1,

“Arterial stiffness is a major risk factor for morbidity and mortality. Although stiffening of the vasculature is a physiological process which occurs during aging, there are many factors resulting in accelerated stiffening. Some conditions, such as aging, cannot be helped; others, however, can be influenced by lifestyle or diet. With the help of new technology and applied scientific research many patients can be monitored and treated after a diagnosed cardiovascular problem”. 

Thrombosis Elastic Stocking,

Life Science Business is developing biomaterials improving the effect of elastic stockings by local transdermal application of natural thrombosis-preventing compounds. This novel approach is specifically aimed for use by consumers at elevated risk for temporarily deep vein thrombosis, such as long-distance travellers who have other risk factors for thrombosis (Factor VLeiden, use of oral contraceptives, etc.).

Company Livan, our distributor for India and Canada

Office Europe:
Life Science Business
Flight Forum 40
5657 DB Eindhoven
The Netherlands

Contact information:
E: info@lifesciencebusiness.nl

Tel.: 0031-(0)40 - 7983021

Office The Middle East :
Life Science Business
P. O. Box: 122022
Sharjah
The UAE